Screener
Immunovant, Inc. IMVT Total Assets
Total Assets at other companies
Other financials
Where this comes from
Reported directly by Immunovant, Inc. in its filing.
Tagged under the XBRL concept us-gaap:Assets.
The source filing: Immunovant, Inc.’s 10-K, filed May 20, 2026.
- Filed
- May 20, 2026, 7:28 AM EDT
- Fiscal year
- FY2026
- Accession
- 0001764013-26-000064
| Line item | March 31, 2026 | March 31, 2025 |
|---|---|---|
| Operating lease right-of-use assets | 72 | 98 |
| Property and equipment, net | 443 | 844 |
| Other assets | 7,680 | 7,618 |
| Total assets | $957,014 | $776,222 |
| Liabilities and Stockholders’ Equity | ||
| Current liabilities: | ||
| Accounts payable | $7,541 | $17,656 |
| Accrued expenses | 96,634 | 50,748 |
Item 8. Financial Statements and Supplementary Data
FAQ
- What is Immunovant, Inc.'s total assets?
- Immunovant, Inc. (IMVT) reported total assets of $957.01M in Q1 2026.
- How has Immunovant, Inc.'s total assets changed year-over-year?
- Immunovant, Inc.'s total assets increased by 23.3% year-over-year, from $776.22M to $957.01M.
- What is the long-term trend for Immunovant, Inc.'s total assets?
- Over 5 years (2021 to 2026), Immunovant, Inc.'s total assets has grown at a 18.3% compound annual growth rate (CAGR), from $412.49M to $957.01M.
- What does total assets mean?
- The sum of everything the company owns — current assets, property, investments, goodwill, intangibles, and all other assets.
Ask your AI about Immunovant, Inc.'s total assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude